1933 IndustriesTGIFF Net Margin % is -9.29% as of Jan. 2026. The stock has 2 warning signs investors should review. Among 953 Drug Manufacturers companies, 1933 Industries ranks worse than 58.66% on this metric.
Net margin is calculated as Net Income divided by its Revenue. 1933 Industries's Net Income for the
three
months ended in Jan. 2026 was $-0.27 Mil. 1933 Industries's Revenue for the
three
months ended in Jan. 2026 was $2.86 Mil. Therefore, 1933 Industries's net margin for the quarter that ended in Jan. 2026 was -9.29%.
The historical rank and industry rank for 1933 Industries's Net Margin % or its related term are showing as below:
TGIFF'
s Net Margin % Range Over the Past 10 Years
Min: -265.44 Med: -79.16 Max: 2.78
Current: 2.78
TGIFF's Net Margin % is ranked worse than 58.66% of 953
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs TGIFF: 2.78
1933 Industries (OTCPK:TGIFF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
1933 Industries Net Margin % Related Terms
1933 Industries Net Margin % Historical Data
* Premium members only.
The historical data trend for 1933 Industries's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, 1933 Industries's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
1933 Industries Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, 1933 Industries's Net Margin % distribution charts can be found below:
* The bar in red indicates where 1933 Industries's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
1933 Industries (TGIFF) has a Net Margin % of -9.29% as of Jan. 2026. Net margin is the ratio of total net income to net sales. View historical data on 1933 Industries and its competitors. According to the industry distribution chart, 1933 Industries ranks #559 out of 953 companies in the Drug Manufacturers industry, placing it in the top 58.7%.
Is 1933 Industries' Net Margin % too high?
1933 Industries' current Net Margin % is -9.29%. Based on the distribution chart, 1933 Industries ranks #559 out of 953 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does 1933 Industries' Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, 1933 Industries ranks #559 out of 953 companies for Net Margin %. This places 1933 Industries in the lower half of its industry. The industry median Net Margin % is 5.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on 1933 Industries and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 1933 Industries's current Net Margin % is -9.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 1933 Industries stock overvalued right now?
Based on GuruFocus' analysis, 1933 Industries (TGIFF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.01, compared to a current price of $0.00 — trading 55% below its estimated fair value. The current Net Margin % is -9.29%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For 1933 Industries (TGIFF), the current Net Margin % is -9.29% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
1933 Industries Inc is a vertically integrated cannabis company. The company is focused on the cultivation and manufacturing of cannabis consumer-branded goods. The Company operates in three segments, referred to as AMA, Infused MFG, and Corporate. AMA is focused on the cultivation and sale of medical and adult-use cannabis products, and Infused MFG is focused on the manufacturing of hemp-derived CBD products. The majority of revenue is generated from the AMA segment. The operations of AMA and Infused MFG are located in the United States. All revenues are earned in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TGIFF has been successfully added to your 